Simon B Goldberg1, Benjamin Shechet1, Christopher R Nicholas2, Chi Wing Ng1, Geetanjali Deole1, Zhuofan Chen1, Charles L Raison3,4. 1. Department of Counseling Psychology, University of Wisconsin - Madison, Madison, WI, USA. 2. Department of Family Medicine and Community Health, University of Wisconsin - Madison, Madison, WI, USA. 3. School of Human Ecology, University of Wisconsin - Madison, Madison, WI, USA. 4. Usona Institute, Fitchberg, WI, USA.
Abstract
BACKGROUND: Scientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychological effects of these substances outside the period of acute intoxication have not been fully characterized. This study aimed to: (1) quantify the effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period; (2) test moderators of these effects; and (3) evaluate adverse effects and risk of bias. METHODS: We conducted a systematic review and meta-analysis of experimental studies (single-group pre-post or randomized controlled trials) that involved administration of psilocybin, ayahuasca, or LSD to clinical or non-clinical samples and assessed psychological outcomes ⩾24 h post-administration. Effects were summarized by study design, timepoint, and outcome domain. RESULTS: A total of 34 studies (24 unique samples, n = 549, mean longest follow-up = 55.34 weeks) were included. Classical psychedelics showed significant within-group pre-post and between-group placebo-controlled effects on a range of outcomes including targeted symptoms within psychiatric samples, negative and positive affect-related measures, social outcomes, and existential/spiritual outcomes, with large between-group effect in these domains (Hedges' gs = 0.84 to 1.08). Moderator tests suggest some effects may be larger in clinical samples. Evidence of effects on big five personality traits and mindfulness was weak. There was no evidence of post-acute adverse effects. CONCLUSIONS: High risk of bias in several domains, heterogeneity across studies, and indications of publication bias for some models highlight the need for careful, large-scale, placebo-controlled randomized trials.
BACKGROUND: Scientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychological effects of these substances outside the period of acute intoxication have not been fully characterized. This study aimed to: (1) quantify the effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period; (2) test moderators of these effects; and (3) evaluate adverse effects and risk of bias. METHODS: We conducted a systematic review and meta-analysis of experimental studies (single-group pre-post or randomized controlled trials) that involved administration of psilocybin, ayahuasca, or LSD to clinical or non-clinical samples and assessed psychological outcomes ⩾24 h post-administration. Effects were summarized by study design, timepoint, and outcome domain. RESULTS: A total of 34 studies (24 unique samples, n = 549, mean longest follow-up = 55.34 weeks) were included. Classical psychedelics showed significant within-group pre-post and between-group placebo-controlled effects on a range of outcomes including targeted symptoms within psychiatric samples, negative and positive affect-related measures, social outcomes, and existential/spiritual outcomes, with large between-group effect in these domains (Hedges' gs = 0.84 to 1.08). Moderator tests suggest some effects may be larger in clinical samples. Evidence of effects on big five personality traits and mindfulness was weak. There was no evidence of post-acute adverse effects. CONCLUSIONS: High risk of bias in several domains, heterogeneity across studies, and indications of publication bias for some models highlight the need for careful, large-scale, placebo-controlled randomized trials.
Authors: Simon Reiche; Leo Hermle; Stefan Gutwinski; Henrik Jungaberle; Peter Gasser; Tomislav Majić Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-09-22 Impact factor: 5.067
Authors: Katrin H Preller; Marcus Herdener; Thomas Pokorny; Amanda Planzer; Rainer Kraehenmann; Philipp Stämpfli; Matthias E Liechti; Erich Seifritz; Franz X Vollenweider Journal: Curr Biol Date: 2017-01-26 Impact factor: 10.834
Authors: Yasmin Schmid; Florian Enzler; Peter Gasser; Eric Grouzmann; Katrin H Preller; Franz X Vollenweider; Rudolf Brenneisen; Felix Müller; Stefan Borgwardt; Matthias E Liechti Journal: Biol Psychiatry Date: 2014-11-29 Impact factor: 13.382
Authors: Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst Journal: J Psychopharmacol Date: 2016-12 Impact factor: 4.153
Authors: Peter Gasser; Dominique Holstein; Yvonne Michel; Rick Doblin; Berra Yazar-Klosinski; Torsten Passie; Rudolf Brenneisen Journal: J Nerv Ment Dis Date: 2014-07 Impact factor: 2.254
Authors: John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane Journal: Front Psychiatry Date: 2021-12-17 Impact factor: 4.157